Calliditas Therapeutics IPO Presentation Deck slide image

Calliditas Therapeutics IPO Presentation Deck

Nefecon - Potential to be first approved treatment for IgAN FPI Nov 2018 150 clinical sites recruiting in 19 countries 2018 2019 Fully recruited 200 patients for Part A of NefigArd (Dec. 21st, 2019) calliditas NeflgArd Part A readout expected in Q4 2020 2020 Expected filing for accelerated approval in U.S. and conditional approval in E.U. in 1H 2021 2021 Anticipated U.S. market launch in 2022 NeflgArd Part B readout in 2022 for full approval 2022 Expected filing of marketing applications in 1H 2021 for accelerated approval in U.S. and conditional approval in E.U., if data from Part A are positive Readout on the differential in loss of kidney function between placebo and treated over two years (eGFR) for validation of surrogate marker expected in 2022 June 2020 19
View entire presentation